论文部分内容阅读
目的 观察半乳糖白蛋白磁性阿霉素纳米粒(Gal-MADM)在正常肝脏中的靶向性,并观察Gal-MADM在全身各脏器的分布特征。方法 使用放射示踪技术,用125I标记纳米粒。肝动脉注射,分别于注药后5、15、30、60、120min处死,立即取肝、肾、心、肺、小肠、脾、及周围血作γ计数。用同样的方法进行白蛋白磁性阿霉素纳米粒(MADM)在大鼠体内分布实验。结果 Gal-MADM和MADM肝摄取分别在注射后5 min后最高,分别为15 054.4 CPM／g和6 186.7 CPM／g,各时相前者的肝摄取率均为同时刻后者的2-3倍。在肝、肾、心、肺、小肠、脾、及周围血的分布两药差异有高度显著性(P<0.05)。结论Gal-MADM在正常肝组织中有明显的主动靶向性,Gal-MADM主要分布肝脏,其它的脏器含量少。
Objective To observe the targeting of Gal-MADM in normal liver and observe the distribution of Gal-MADM in various organs of the body. Methods Using radioactive tracing techniques, nanoparticles were labeled with 125I. Hepatic artery injection, respectively, after injection of 5,15,30,60,120 min death, immediately take liver, kidney, heart, lung, small intestine, spleen, and peripheral blood for γ count. In the same way, albumin magnetic doxorubicin nanoparticles (MADM) were distributed in rats. Results The hepatic uptake of Gal-MADM and MADM was the highest at 5 min after injection, 15 054.4 CPM / g and 6 186.7 CPM / g, respectively. . The differences of the two drugs in the distribution of liver, kidney, heart, lung, small intestine, spleen and peripheral blood were highly significant (P <0.05). Conclusion Gal-MADM has obvious active targeting in normal liver tissue. Gal-MADM mainly distributes in the liver, while other organs have less content.